These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35702631)

  • 1. A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis.
    Katki HA; Bebu I
    J R Stat Soc Ser A Stat Soc; 2021 Jul; 184(3):887-903. PubMed ID: 35702631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Youden's index with net benefit: A feasible approach for optimal-threshold determination in shared decision making.
    Lin S; Ma Y; Zou H
    J Eval Clin Pract; 2020 Apr; 26(2):551-558. PubMed ID: 31738475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis.
    Katki HA
    Stat Med; 2019 Jul; 38(16):2943-2955. PubMed ID: 31037749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
    Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
    Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
    Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators.
    Van Calster B; Wynants L; Verbeek JFM; Verbakel JY; Christodoulou E; Vickers AJ; Roobol MJ; Steyerberg EW
    Eur Urol; 2018 Dec; 74(6):796-804. PubMed ID: 30241973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation.
    Farrar D; Simmonds M; Griffin S; Duarte A; Lawlor DA; Sculpher M; Fairley L; Golder S; Tuffnell D; Bland M; Dunne F; Whitelaw D; Wright J; Sheldon TA
    Health Technol Assess; 2016 Nov; 20(86):1-348. PubMed ID: 27917777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.
    Goodacre S; Sampson F; Stevenson M; Wailoo A; Sutton A; Thomas S; Locker T; Ryan A
    Health Technol Assess; 2006 May; 10(15):1-168, iii-iv. PubMed ID: 16707072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
    Lee JM; McMahon PM; Kong CY; Kopans DB; Ryan PD; Ozanne EM; Halpern EF; Gazelle GS
    Radiology; 2010 Mar; 254(3):793-800. PubMed ID: 20177093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
    de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
    Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative approach identified optimal risk thresholds for treatment indication: an illustration in coronary heart disease.
    van Giessen A; de Wit GA; Moons KGM; Dorresteijn JAN; Koffijberg H
    J Clin Epidemiol; 2018 Feb; 94():122-131. PubMed ID: 28986242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.